Drug intelligence / Profile preview

CTRO-2018

Development stage: Preclinical
Lead developer: insitro
Modality: MicroRNA (miRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics

Overview

CTRO-2018 is an oligonucleotide therapeutic currently in the molecule design phase for the treatment of amyotrophic lateral sclerosis (ALS). Developed by insitro in collaboration with Bristol Myers Squibb, the program was identified using insitro's machine learning-enabled Virtual Human platform, which models disease phenotypes in patient-derived induced pluripotent stem cells (iPSCs) to discover novel therapeutic targets.

Other names: CTRO 2018CTRO2018CTRO-2018

Beyond the preview

Go deeper on CTRO-2018.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CTRO-2018.

Explore the full profile